SlideShare a Scribd company logo
Minimizing secondary injury
Victoria McCredie MBChB PhD
Assistant Professor
University of Toronto
Conflicts of interest
• Nothing to declare
Outline
The importance of neuroprotection
Secondary brain injury targets
Neuroprotection at the bedside
Outline
The importance of neuroprotection
Secondary brain injury targets
Neuroprotection at the bedside
Neuroprotection:
an important goal
Maas AI et al. The Lancet Neurology 2008
Macrovascular
Microvascular
Molecular
Importance of differential pathophysiological mechanisms
STRUCTURE
Microvascular
Molecular
Inflammation
Receptor-mediated damage
Oxidative damage
Calcium-mediated damage
Dynamic and
PROGRESSIVE
process following
injury
Adapted from Stocchetti N et al. Crit Care 2013
Excitotoxicity
Edema
Mitochondrial dysfunction
Impaired oxygen diffusion
Impaired autoregulation, reduced CBF
Energy dysfunction
Hours Days
Inflammation
Cortical depolarizations
Neurodegeneration
TIME
Importance of differential pathophysiological mechanisms
Neuroprotective agents
• The focus for neuroprotective strategies has
mostly been on pharmacological agents
• Preliminary results of these agents were often
encouraging
• Unfortunately, clinical trials using these candidate
neuroprotective agents have consistently
produced disappointing results
• To date, there is no targeted pharmacological
treatment that effectively limits the progression of
secondary injury
SYNAPSE
EPO-TBI
PEG-SOD
Tirilazad
Selfotel
Traxoprodil
Dexanabinol
Magnesium Sulfate
COBRIT
Perhaps deflected attention from the
development of neuroprotective
strategies and trials addressing
everyday ICU management
Outcomes improving over time
• Despite repeated failures in pharmacological neuroprotection,
outcomes for TBI patients have improved
• Secular trend in general critical care organization and delivery of care
improvements over the past 2 decades
• Likely that the organization of intensive treatment has contributed,
offering a different kind of neuroprotection based on careful
prevention and limitation of intracranial and systemic threats
Kramer & Zygun. Can J Anesth 2013 Oct;60(10):966-75
Rosenfeld et al. Lancet. 2012 Sep 22;380(9847)
Outline
The importance of neuroprotection
Secondary brain injury targets
Neuroprotection at the bedside
Neurophysiologic
targets
• Hypoxemia/hyperoxemia
• Hypotension
• Intracranial hypertension
• Hypoglycemia
• Fever
Neurophysiologic concepts
Secondary
insult ‘dose’
Individualized
thresholds
Trajectory
Neurophysiologic concepts
Secondary
insult ‘dose’
Individualized
thresholds
Trajectory
Time is brain
Secondary insult ‘dose’
Pressure*time burden of intracranial
hypertension
Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
ICP
‘dose’Increasing
time spent at
ICP level
ICP value
Worse
outcome
Neurophysiologic concepts
Secondary
insult ‘dose’
Individualized
thresholds
Trajectory
‘One-size-fits-all’
approach
Systolic blood pressure thresholds
Systolic blood pressure to decrease mortality:
• Patients 15 to 49 yrs: SBP >=110 mmHg
• Patients 50 to 69 yrs: at >=100 mmHg
• Patients >70 yrs: SBP >=110 mmHg
https://www.braintrauma.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed#/:guideline/17-cerebral-perfusion-pressure-thresholds
85
95
105
115
125
135
0 20 40 60 80 100
SBP
Age
• Recommended target CPP for survival and favorable
outcomes between 60-70 mmHg
• Unclear whether 60 or 70 mm Hg is the minimum optimal
CPP threshold
• May depend upon the patient’s autoregulatory status
https://www.braintrauma.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed#/:guideline/17-cerebral-perfusion-pressure-thresholds
Cerebral perfusion pressure thresholds
Assessment of cerebral autoregulation state
All comers
ICP 20mmHg
30 mins
Ability to
tolerate burden
of intracranial
hypertension
Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
CA intact
ICP 20mmHg
150
mins
Assessment of cerebral autoregulation state
Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
CA disrupted
ICP 20mmHg
15 mins
Assessment of cerebral autoregulation state
INABILITY to
tolerate burden
of intracranial
hypertension
Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
Neurophysiologic concepts
Secondary
insult ‘dose’
Individualized
thresholds
Trajectory
Are these two patients different?
ICP 23 ICP 21
PATIENT A PATIENT B
Meyfroidt & Citerio. Neurosurgery 2017 Jul 1;81(1):E1
Which patient are you more concerned about now?
ICP 23
ICP 21
ICP 9
PATIENT A PATIENT B
Meyfroidt & Citerio. Neurosurgery 2017 Jul 1;81(1):E1
Outline
The importance of neuroprotection
Secondary brain injury targets
Neuroprotection at the bedside
Neuroprotection at the bedside
Detection of secondary insults
at the bedside
1
Translation of neuroprotective
strategies at the bedside
2
Integrated neurophysiologic
monitoring
Standardized management protocol
Neuroprotection at the bedside
Detection of secondary insults
at the bedside
1
Translation of neuroprotective
strategies at the bedside
2
Integrated neurophysiologic
monitoring
Standardized management protocol
Why is neurological monitoring so important?
1. First 48 hours, up to 40% of TBI
patients show a clinically relevant
neurological worsening
2. NO neurological deterioration vs
neurological deterioration:
• Mortality rate of 9.6% vs 56.4%
• Favorable outcome of 67.8% vs 29.1%
Brown et al. J Trauma 2007 Jun;62(6):1339-44 Iaccarino et al. J Neurosurg 2014 Apr;120(4):908-18
Juul et al. J Neurosurg 2000 Jan;92(1):1-6 Maas et al. Lancet Neurol 2006 Jan;5(1):38-45
Morris et al. Neurosurgery 1998 Dec;43(6):1369-72
Reasons for neurological deterioration:
1. Increased intracranial volume 63.4%
2. Systemic complications 12.5%
3. No definable cause 12.5%
4. Seizures 6.7%
5. Cerebral ischemia 4.8%
Day 2 ICU TBI
• 42 year old male
• Severe TBI
• GCS E1 M4 VT
• Brainstem reflexes intact
• Sedated for ICP/brain
protective ventilation
How do we detect secondary
brain insults in this comatose
patient?
Standard
monitoring ICP/CPP
Impaired brain
metabolism
Brain tissue
hypoxia
Reduced cerebral
blood flow
What we know
What we need to know
Pressure
Flow
Oxygenation
Metabolism
Randomized
ICP <20 mmHg
ICP <20 mmHg
AND
PbtO2 >20 mmHg
Okonkwo et al. CCM 2017
Reduction in brain tissue hypoxia burden
ICP only
PbtO2 and ICP
Tiered PbtO2 management
• Decreased total duration of
hypoxia by 66%
• Decreased average depth of
hypoxia by 72%
• Reduced area under the curve
by 77%Total hypoxia burden (hrs * mmHg)
It remains to be demonstrated whether
multimodal monitoring-guided therapy is
able to improve outcome.
Neuroprotection at the bedside
Detection of secondary insults
at the bedside
1
Translation of neuroprotective
strategies at the bedside
2
Integrated neurophysiologic
monitoring
Standardized management protocol
Neurophysiologic-driven protocols in TBI
McCredie et al. Crit Care Med. 2018 Jul;46(7):1139-1149
How can protocols improve patient care?
• Aims to improve outcomes by guiding consistent patient care:
1. Facilitate communication
2. Reduce cognitive load
3. Coordinate the interdisciplinary team
4. Increase the adoption of evidence-based interventions and
improve adherence to guidelines
Chang et al. Critical Care 2012
Neurocritical care interventions
ICU STRUCTURE:
DEDICATED NCC UNITS VS
GENERAL ICU
PROCESS OF CARE:
PRESENCE OF A
STANDARDIZED TBI
MANAGEMENT PROTOCOL
McCredie et al. Crit Care Med. 2018 Jul;46(7):1139-1149
ICP
PbrO2
Results
Dedicated neurocritical care
units were not associated with
lower risk-adjusted in-hospital
mortality
aOR 0.97 (95% CI 0.80-1.19)
Standardized management
protocols were associated with
improved in-hospital mortality
aOR 0.77 (95% CI 0.63-0.93)
McCredie et al. Crit Care Med. 2018 Jul;46(7):1139-1149
In conclusion
• Our understanding of secondary brain injury mechanisms and physiologic
responses to treatment is continually evolving
• Moving forward, we must better understand whether these neurophysiologic
parameters are modifiable, and whether modification affects relevant outcomes
• Neurophysiologic monitoring at the bedside is a DYNAMIC process, not a single
measurement
• Integrated neuromonitoring may improve situational awareness and allow an
individualized approach to therapy
Thanks
Victoria.McCredie@uhn.ca
@UofTNeuroCrit
@Vicvovie
Questions

More Related Content

What's hot

Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)
Sudhir Kumar
 
SAH outcome and rehabilitation
SAH outcome and rehabilitationSAH outcome and rehabilitation
SAH outcome and rehabilitation
Dhaval Shukla
 
Nccu journal club 2.5.13
Nccu journal club 2.5.13Nccu journal club 2.5.13
Nccu journal club 2.5.13
Joshua Kornbluth
 
Responsive Neurostimulation (RNS) for Intractable Epilepsy
Responsive Neurostimulation (RNS) for Intractable EpilepsyResponsive Neurostimulation (RNS) for Intractable Epilepsy
Responsive Neurostimulation (RNS) for Intractable Epilepsy
Allina Health
 
Neuroprotective agents use for traumatic brain injury - modified for thesis d...
Neuroprotective agents use for traumatic brain injury - modified for thesis d...Neuroprotective agents use for traumatic brain injury - modified for thesis d...
Neuroprotective agents use for traumatic brain injury - modified for thesis d...
Mohammad Meŝkini محمد مشکینی
 
“8th National Biennial Conference on Medical Informatics 2012”
“8th National Biennial Conference on Medical Informatics 2012” “8th National Biennial Conference on Medical Informatics 2012”
“8th National Biennial Conference on Medical Informatics 2012”
Ashu Ash
 
The Neuroprotective Effects of Ketones in TBI
The Neuroprotective Effects of Ketones in TBIThe Neuroprotective Effects of Ketones in TBI
The Neuroprotective Effects of Ketones in TBI
Bryan Barksdale
 
Coma Arousal Therapy
Coma Arousal TherapyComa Arousal Therapy
Coma Arousal Therapy
Dhaval Shukla
 
IRJET- Portable Supporting Device for Narcoleptic Patients
IRJET- Portable Supporting Device for Narcoleptic PatientsIRJET- Portable Supporting Device for Narcoleptic Patients
IRJET- Portable Supporting Device for Narcoleptic Patients
IRJET Journal
 
CIACI_2015
CIACI_2015CIACI_2015
IVIG IN CIDP 17
IVIG IN CIDP 17IVIG IN CIDP 17
IVIG IN CIDP 17
NeurologyKota
 
Rescue therapy headache
Rescue therapy headacheRescue therapy headache
Rescue therapy headache
GaetanoTerranova2
 
Chronic inflammatory demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating Polyradiculoneuropathy Chronic inflammatory demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating Polyradiculoneuropathy
Ajay Kumar
 
Vns Therapy™ System For Weikong For Print
Vns Therapy™ System For Weikong For PrintVns Therapy™ System For Weikong For Print
Vns Therapy™ System For Weikong For Print
calaf0618
 
Neuroprotective agents for traumatic brain injury
Neuroprotective agents for traumatic brain injuryNeuroprotective agents for traumatic brain injury
Neuroprotective agents for traumatic brain injury
Mohammad Meŝkini محمد مشکینی
 
1455 wilson
1455 wilson1455 wilson
1455 wilson
SMACC Conference
 
Withdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugsWithdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugs
Pramod Krishnan
 
Short and Long-term Outcomes from Sport-related Concussions: What Are the Rea...
Short and Long-term Outcomes from Sport-related Concussions: What Are the Rea...Short and Long-term Outcomes from Sport-related Concussions: What Are the Rea...
Short and Long-term Outcomes from Sport-related Concussions: What Are the Rea...
University of Michigan Injury Center
 
Switching therapy in Multiple sclerosis
Switching therapy in Multiple sclerosisSwitching therapy in Multiple sclerosis
Switching therapy in Multiple sclerosis
Divya Shilpa
 
Journal presenatation on tms
Journal presenatation on tmsJournal presenatation on tms
Journal presenatation on tms
Sudhen Sumesh Kumar
 

What's hot (20)

Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)
 
SAH outcome and rehabilitation
SAH outcome and rehabilitationSAH outcome and rehabilitation
SAH outcome and rehabilitation
 
Nccu journal club 2.5.13
Nccu journal club 2.5.13Nccu journal club 2.5.13
Nccu journal club 2.5.13
 
Responsive Neurostimulation (RNS) for Intractable Epilepsy
Responsive Neurostimulation (RNS) for Intractable EpilepsyResponsive Neurostimulation (RNS) for Intractable Epilepsy
Responsive Neurostimulation (RNS) for Intractable Epilepsy
 
Neuroprotective agents use for traumatic brain injury - modified for thesis d...
Neuroprotective agents use for traumatic brain injury - modified for thesis d...Neuroprotective agents use for traumatic brain injury - modified for thesis d...
Neuroprotective agents use for traumatic brain injury - modified for thesis d...
 
“8th National Biennial Conference on Medical Informatics 2012”
“8th National Biennial Conference on Medical Informatics 2012” “8th National Biennial Conference on Medical Informatics 2012”
“8th National Biennial Conference on Medical Informatics 2012”
 
The Neuroprotective Effects of Ketones in TBI
The Neuroprotective Effects of Ketones in TBIThe Neuroprotective Effects of Ketones in TBI
The Neuroprotective Effects of Ketones in TBI
 
Coma Arousal Therapy
Coma Arousal TherapyComa Arousal Therapy
Coma Arousal Therapy
 
IRJET- Portable Supporting Device for Narcoleptic Patients
IRJET- Portable Supporting Device for Narcoleptic PatientsIRJET- Portable Supporting Device for Narcoleptic Patients
IRJET- Portable Supporting Device for Narcoleptic Patients
 
CIACI_2015
CIACI_2015CIACI_2015
CIACI_2015
 
IVIG IN CIDP 17
IVIG IN CIDP 17IVIG IN CIDP 17
IVIG IN CIDP 17
 
Rescue therapy headache
Rescue therapy headacheRescue therapy headache
Rescue therapy headache
 
Chronic inflammatory demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating Polyradiculoneuropathy Chronic inflammatory demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating Polyradiculoneuropathy
 
Vns Therapy™ System For Weikong For Print
Vns Therapy™ System For Weikong For PrintVns Therapy™ System For Weikong For Print
Vns Therapy™ System For Weikong For Print
 
Neuroprotective agents for traumatic brain injury
Neuroprotective agents for traumatic brain injuryNeuroprotective agents for traumatic brain injury
Neuroprotective agents for traumatic brain injury
 
1455 wilson
1455 wilson1455 wilson
1455 wilson
 
Withdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugsWithdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugs
 
Short and Long-term Outcomes from Sport-related Concussions: What Are the Rea...
Short and Long-term Outcomes from Sport-related Concussions: What Are the Rea...Short and Long-term Outcomes from Sport-related Concussions: What Are the Rea...
Short and Long-term Outcomes from Sport-related Concussions: What Are the Rea...
 
Switching therapy in Multiple sclerosis
Switching therapy in Multiple sclerosisSwitching therapy in Multiple sclerosis
Switching therapy in Multiple sclerosis
 
Journal presenatation on tms
Journal presenatation on tmsJournal presenatation on tms
Journal presenatation on tms
 

Similar to Victoria McCredie minimizing secondary injury #ISICEM19 #IFAD2019

Debate: Neurocritical Care Improves Outcomes in Severe TBI
Debate: Neurocritical Care Improves Outcomes in Severe TBIDebate: Neurocritical Care Improves Outcomes in Severe TBI
Debate: Neurocritical Care Improves Outcomes in Severe TBI
SMACC Conference
 
Anesthesia and geriatrics 2021 no recording
Anesthesia and geriatrics 2021 no recordingAnesthesia and geriatrics 2021 no recording
Anesthesia and geriatrics 2021 no recording
Marc Evans Abat
 
Hypothermia for TBI FINAL
Hypothermia for TBI FINAL Hypothermia for TBI FINAL
Hypothermia for TBI FINAL
Nancy Kelly
 
Pain management in neurosurgical patients
Pain management in neurosurgical patientsPain management in neurosurgical patients
Pain management in neurosurgical patients
Rajendra Institute of Medical Sciences, Ranchi.
 
Neuroprotection in neurology
Neuroprotection in neurologyNeuroprotection in neurology
Neuroprotection in neurology
Swiss Multiple Sclerosis Society
 
2010.05.20 clinicians view on regeneration
2010.05.20 clinicians view on regeneration2010.05.20 clinicians view on regeneration
2010.05.20 clinicians view on regeneration
neithan
 
Lessons from the TTM trial and planning for the nexst
Lessons from the TTM trial and planning for the nexstLessons from the TTM trial and planning for the nexst
Lessons from the TTM trial and planning for the nexst
scanFOAM
 
ischemic stroke and hemorrhagic in adult
ischemic stroke and hemorrhagic  in adultischemic stroke and hemorrhagic  in adult
ischemic stroke and hemorrhagic in adult
DrJoharAljohar
 
Annovis Presentation - February 2021
Annovis Presentation - February 2021Annovis Presentation - February 2021
Annovis Presentation - February 2021
RedChip Companies, Inc.
 
BTF-Guidelines-for-TBI-Management.pdf
BTF-Guidelines-for-TBI-Management.pdfBTF-Guidelines-for-TBI-Management.pdf
BTF-Guidelines-for-TBI-Management.pdf
TungToManh
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain Injury
Brian Piper
 
ANVS (NYSE American) Annovis Presentation - January 2021
ANVS (NYSE American) Annovis Presentation -  January 2021ANVS (NYSE American) Annovis Presentation -  January 2021
ANVS (NYSE American) Annovis Presentation - January 2021
RedChip Companies, Inc.
 
Dietrich, Dalton
Dietrich, DaltonDietrich, Dalton
Rescue icp
Rescue icpRescue icp
Rescue icp
Andrew Alalade
 
AANN 2016, Neurocritical Care Without Limits- An Alternative nCCU Model
AANN 2016, Neurocritical Care Without Limits- An Alternative nCCU ModelAANN 2016, Neurocritical Care Without Limits- An Alternative nCCU Model
AANN 2016, Neurocritical Care Without Limits- An Alternative nCCU Model
Troy Gideon RN, BSN, MBA
 
Tugas Jurnal Reading Neurosonology terbaru.pptx
Tugas Jurnal Reading Neurosonology terbaru.pptxTugas Jurnal Reading Neurosonology terbaru.pptx
Tugas Jurnal Reading Neurosonology terbaru.pptx
AzfahsyaRafifYusro
 
thesis plan dm pptx for medical hoya goya
thesis plan dm pptx for medical hoya goyathesis plan dm pptx for medical hoya goya
thesis plan dm pptx for medical hoya goya
vijay prakash
 
Evidence based ICU
Evidence based ICUEvidence based ICU
Evidence based ICU
mathilda30
 
post operative cognitive dysfunction
post operative cognitive dysfunctionpost operative cognitive dysfunction
post operative cognitive dysfunction
priyanka gupta
 
Traumatic Brain Injury.pptx
Traumatic Brain Injury.pptxTraumatic Brain Injury.pptx
Traumatic Brain Injury.pptx
Б М
 

Similar to Victoria McCredie minimizing secondary injury #ISICEM19 #IFAD2019 (20)

Debate: Neurocritical Care Improves Outcomes in Severe TBI
Debate: Neurocritical Care Improves Outcomes in Severe TBIDebate: Neurocritical Care Improves Outcomes in Severe TBI
Debate: Neurocritical Care Improves Outcomes in Severe TBI
 
Anesthesia and geriatrics 2021 no recording
Anesthesia and geriatrics 2021 no recordingAnesthesia and geriatrics 2021 no recording
Anesthesia and geriatrics 2021 no recording
 
Hypothermia for TBI FINAL
Hypothermia for TBI FINAL Hypothermia for TBI FINAL
Hypothermia for TBI FINAL
 
Pain management in neurosurgical patients
Pain management in neurosurgical patientsPain management in neurosurgical patients
Pain management in neurosurgical patients
 
Neuroprotection in neurology
Neuroprotection in neurologyNeuroprotection in neurology
Neuroprotection in neurology
 
2010.05.20 clinicians view on regeneration
2010.05.20 clinicians view on regeneration2010.05.20 clinicians view on regeneration
2010.05.20 clinicians view on regeneration
 
Lessons from the TTM trial and planning for the nexst
Lessons from the TTM trial and planning for the nexstLessons from the TTM trial and planning for the nexst
Lessons from the TTM trial and planning for the nexst
 
ischemic stroke and hemorrhagic in adult
ischemic stroke and hemorrhagic  in adultischemic stroke and hemorrhagic  in adult
ischemic stroke and hemorrhagic in adult
 
Annovis Presentation - February 2021
Annovis Presentation - February 2021Annovis Presentation - February 2021
Annovis Presentation - February 2021
 
BTF-Guidelines-for-TBI-Management.pdf
BTF-Guidelines-for-TBI-Management.pdfBTF-Guidelines-for-TBI-Management.pdf
BTF-Guidelines-for-TBI-Management.pdf
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain Injury
 
ANVS (NYSE American) Annovis Presentation - January 2021
ANVS (NYSE American) Annovis Presentation -  January 2021ANVS (NYSE American) Annovis Presentation -  January 2021
ANVS (NYSE American) Annovis Presentation - January 2021
 
Dietrich, Dalton
Dietrich, DaltonDietrich, Dalton
Dietrich, Dalton
 
Rescue icp
Rescue icpRescue icp
Rescue icp
 
AANN 2016, Neurocritical Care Without Limits- An Alternative nCCU Model
AANN 2016, Neurocritical Care Without Limits- An Alternative nCCU ModelAANN 2016, Neurocritical Care Without Limits- An Alternative nCCU Model
AANN 2016, Neurocritical Care Without Limits- An Alternative nCCU Model
 
Tugas Jurnal Reading Neurosonology terbaru.pptx
Tugas Jurnal Reading Neurosonology terbaru.pptxTugas Jurnal Reading Neurosonology terbaru.pptx
Tugas Jurnal Reading Neurosonology terbaru.pptx
 
thesis plan dm pptx for medical hoya goya
thesis plan dm pptx for medical hoya goyathesis plan dm pptx for medical hoya goya
thesis plan dm pptx for medical hoya goya
 
Evidence based ICU
Evidence based ICUEvidence based ICU
Evidence based ICU
 
post operative cognitive dysfunction
post operative cognitive dysfunctionpost operative cognitive dysfunction
post operative cognitive dysfunction
 
Traumatic Brain Injury.pptx
Traumatic Brain Injury.pptxTraumatic Brain Injury.pptx
Traumatic Brain Injury.pptx
 

More from International Fluid Academy

20. #ifad2019 fluid therapy in massive bleeding (llau)
20. #ifad2019 fluid therapy in massive bleeding (llau)20. #ifad2019 fluid therapy in massive bleeding (llau)
20. #ifad2019 fluid therapy in massive bleeding (llau)
International Fluid Academy
 
19. #ifad2019 triggering celular oxygenation (carmona)
19. #ifad2019 triggering celular oxygenation (carmona)19. #ifad2019 triggering celular oxygenation (carmona)
19. #ifad2019 triggering celular oxygenation (carmona)
International Fluid Academy
 
18. #ifad2019 heart lung interactions (aldecoa)
18. #ifad2019 heart lung interactions (aldecoa)18. #ifad2019 heart lung interactions (aldecoa)
18. #ifad2019 heart lung interactions (aldecoa)
International Fluid Academy
 
16. #ifad219 report of fluid day spain (colomina)
16. #ifad219 report of fluid day spain (colomina)16. #ifad219 report of fluid day spain (colomina)
16. #ifad219 report of fluid day spain (colomina)
International Fluid Academy
 
14. #ifad2019 is there a place left for album (caironi)
14. #ifad2019 is there a place left for album (caironi)14. #ifad2019 is there a place left for album (caironi)
14. #ifad2019 is there a place left for album (caironi)
International Fluid Academy
 
12. #ifad2019 everything you nbeed to know about maintenance and resuscitatio...
12. #ifad2019 everything you nbeed to know about maintenance and resuscitatio...12. #ifad2019 everything you nbeed to know about maintenance and resuscitatio...
12. #ifad2019 everything you nbeed to know about maintenance and resuscitatio...
International Fluid Academy
 
9. #ifad2019 review of recent fluid trials (funcke)
9. #ifad2019 review of recent fluid trials (funcke)9. #ifad2019 review of recent fluid trials (funcke)
9. #ifad2019 review of recent fluid trials (funcke)
International Fluid Academy
 
8. #ifad2019 review of recent monitoring trials (edwards)
8. #ifad2019 review of recent monitoring trials (edwards)8. #ifad2019 review of recent monitoring trials (edwards)
8. #ifad2019 review of recent monitoring trials (edwards)
International Fluid Academy
 
7. #ifad2019 how to assess volemic status (langer)
7. #ifad2019 how to assess volemic status (langer)7. #ifad2019 how to assess volemic status (langer)
7. #ifad2019 how to assess volemic status (langer)
International Fluid Academy
 
6. #ifad2019 how to measure fluid resppnsiveness (alonso inigo)
6. #ifad2019 how to measure fluid resppnsiveness (alonso inigo)6. #ifad2019 how to measure fluid resppnsiveness (alonso inigo)
6. #ifad2019 how to measure fluid resppnsiveness (alonso inigo)
International Fluid Academy
 
5. #ifad2019 the role of the glycocalyx (chappell)
5. #ifad2019 the role of the glycocalyx (chappell)5. #ifad2019 the role of the glycocalyx (chappell)
5. #ifad2019 the role of the glycocalyx (chappell)
International Fluid Academy
 
21. #ifad2019 how to guide deresuscitation (malbrain)
21. #ifad2019 how to guide deresuscitation (malbrain)21. #ifad2019 how to guide deresuscitation (malbrain)
21. #ifad2019 how to guide deresuscitation (malbrain)
International Fluid Academy
 
4. #ifad2019 what happened in meantime literature on fluid physiology (cair...
4. #ifad2019 what happened in meantime   literature on fluid physiology (cair...4. #ifad2019 what happened in meantime   literature on fluid physiology (cair...
4. #ifad2019 what happened in meantime literature on fluid physiology (cair...
International Fluid Academy
 
1. time to look back, what happened in the past 40 years in critical care #uz...
1. time to look back, what happened in the past 40 years in critical care #uz...1. time to look back, what happened in the past 40 years in critical care #uz...
1. time to look back, what happened in the past 40 years in critical care #uz...
International Fluid Academy
 
2. (r)evolution in nutrition in critically ill #uzb40 icu (de waele e)
2. (r)evolution in nutrition in critically ill #uzb40 icu (de waele e)2. (r)evolution in nutrition in critically ill #uzb40 icu (de waele e)
2. (r)evolution in nutrition in critically ill #uzb40 icu (de waele e)
International Fluid Academy
 
3. (r)evolution in hemodynamic monitoring in critically ill #uzb40 icu (monnet)
3. (r)evolution in hemodynamic monitoring in critically ill #uzb40 icu (monnet)3. (r)evolution in hemodynamic monitoring in critically ill #uzb40 icu (monnet)
3. (r)evolution in hemodynamic monitoring in critically ill #uzb40 icu (monnet)
International Fluid Academy
 
4. (r)evolution in respiratory failure in critically ill #uzb40 icu (reuter)
4. (r)evolution in respiratory failure in critically ill #uzb40 icu (reuter)4. (r)evolution in respiratory failure in critically ill #uzb40 icu (reuter)
4. (r)evolution in respiratory failure in critically ill #uzb40 icu (reuter)
International Fluid Academy
 
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
International Fluid Academy
 
6. (r)evolution in neurologic monitoring and tbi #uzb40 icu (taccone)
6. (r)evolution in neurologic monitoring and tbi #uzb40 icu (taccone)6. (r)evolution in neurologic monitoring and tbi #uzb40 icu (taccone)
6. (r)evolution in neurologic monitoring and tbi #uzb40 icu (taccone)
International Fluid Academy
 
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
International Fluid Academy
 

More from International Fluid Academy (20)

20. #ifad2019 fluid therapy in massive bleeding (llau)
20. #ifad2019 fluid therapy in massive bleeding (llau)20. #ifad2019 fluid therapy in massive bleeding (llau)
20. #ifad2019 fluid therapy in massive bleeding (llau)
 
19. #ifad2019 triggering celular oxygenation (carmona)
19. #ifad2019 triggering celular oxygenation (carmona)19. #ifad2019 triggering celular oxygenation (carmona)
19. #ifad2019 triggering celular oxygenation (carmona)
 
18. #ifad2019 heart lung interactions (aldecoa)
18. #ifad2019 heart lung interactions (aldecoa)18. #ifad2019 heart lung interactions (aldecoa)
18. #ifad2019 heart lung interactions (aldecoa)
 
16. #ifad219 report of fluid day spain (colomina)
16. #ifad219 report of fluid day spain (colomina)16. #ifad219 report of fluid day spain (colomina)
16. #ifad219 report of fluid day spain (colomina)
 
14. #ifad2019 is there a place left for album (caironi)
14. #ifad2019 is there a place left for album (caironi)14. #ifad2019 is there a place left for album (caironi)
14. #ifad2019 is there a place left for album (caironi)
 
12. #ifad2019 everything you nbeed to know about maintenance and resuscitatio...
12. #ifad2019 everything you nbeed to know about maintenance and resuscitatio...12. #ifad2019 everything you nbeed to know about maintenance and resuscitatio...
12. #ifad2019 everything you nbeed to know about maintenance and resuscitatio...
 
9. #ifad2019 review of recent fluid trials (funcke)
9. #ifad2019 review of recent fluid trials (funcke)9. #ifad2019 review of recent fluid trials (funcke)
9. #ifad2019 review of recent fluid trials (funcke)
 
8. #ifad2019 review of recent monitoring trials (edwards)
8. #ifad2019 review of recent monitoring trials (edwards)8. #ifad2019 review of recent monitoring trials (edwards)
8. #ifad2019 review of recent monitoring trials (edwards)
 
7. #ifad2019 how to assess volemic status (langer)
7. #ifad2019 how to assess volemic status (langer)7. #ifad2019 how to assess volemic status (langer)
7. #ifad2019 how to assess volemic status (langer)
 
6. #ifad2019 how to measure fluid resppnsiveness (alonso inigo)
6. #ifad2019 how to measure fluid resppnsiveness (alonso inigo)6. #ifad2019 how to measure fluid resppnsiveness (alonso inigo)
6. #ifad2019 how to measure fluid resppnsiveness (alonso inigo)
 
5. #ifad2019 the role of the glycocalyx (chappell)
5. #ifad2019 the role of the glycocalyx (chappell)5. #ifad2019 the role of the glycocalyx (chappell)
5. #ifad2019 the role of the glycocalyx (chappell)
 
21. #ifad2019 how to guide deresuscitation (malbrain)
21. #ifad2019 how to guide deresuscitation (malbrain)21. #ifad2019 how to guide deresuscitation (malbrain)
21. #ifad2019 how to guide deresuscitation (malbrain)
 
4. #ifad2019 what happened in meantime literature on fluid physiology (cair...
4. #ifad2019 what happened in meantime   literature on fluid physiology (cair...4. #ifad2019 what happened in meantime   literature on fluid physiology (cair...
4. #ifad2019 what happened in meantime literature on fluid physiology (cair...
 
1. time to look back, what happened in the past 40 years in critical care #uz...
1. time to look back, what happened in the past 40 years in critical care #uz...1. time to look back, what happened in the past 40 years in critical care #uz...
1. time to look back, what happened in the past 40 years in critical care #uz...
 
2. (r)evolution in nutrition in critically ill #uzb40 icu (de waele e)
2. (r)evolution in nutrition in critically ill #uzb40 icu (de waele e)2. (r)evolution in nutrition in critically ill #uzb40 icu (de waele e)
2. (r)evolution in nutrition in critically ill #uzb40 icu (de waele e)
 
3. (r)evolution in hemodynamic monitoring in critically ill #uzb40 icu (monnet)
3. (r)evolution in hemodynamic monitoring in critically ill #uzb40 icu (monnet)3. (r)evolution in hemodynamic monitoring in critically ill #uzb40 icu (monnet)
3. (r)evolution in hemodynamic monitoring in critically ill #uzb40 icu (monnet)
 
4. (r)evolution in respiratory failure in critically ill #uzb40 icu (reuter)
4. (r)evolution in respiratory failure in critically ill #uzb40 icu (reuter)4. (r)evolution in respiratory failure in critically ill #uzb40 icu (reuter)
4. (r)evolution in respiratory failure in critically ill #uzb40 icu (reuter)
 
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
5. (r)evolution in kidney failure in critically ill #uzb40 icu (molnar)
 
6. (r)evolution in neurologic monitoring and tbi #uzb40 icu (taccone)
6. (r)evolution in neurologic monitoring and tbi #uzb40 icu (taccone)6. (r)evolution in neurologic monitoring and tbi #uzb40 icu (taccone)
6. (r)evolution in neurologic monitoring and tbi #uzb40 icu (taccone)
 
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
 

Recently uploaded

CCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer RehabpptxCCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer Rehabpptx
Canadian Cancer Survivor Network
 
How Effective is Homeopathic Medicine for Anxiety and Stress Relief.pdf
How Effective is Homeopathic Medicine for Anxiety and Stress Relief.pdfHow Effective is Homeopathic Medicine for Anxiety and Stress Relief.pdf
How Effective is Homeopathic Medicine for Anxiety and Stress Relief.pdf
Dharma Homoeopathy
 
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareStem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Dr. David Greene Arizona
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DR Jag Mohan Prajapati
 
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic IllnessesPrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx Program
 
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
rightmanforbloodline
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
priyabhojwani1200
 
Can Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdfCan Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdf
Dharma Homoeopathy
 
Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.
Vishal kr Thakur
 
Anxiety, Trauma and Stressor Related Disorder.pptx
Anxiety, Trauma and Stressor Related Disorder.pptxAnxiety, Trauma and Stressor Related Disorder.pptx
Anxiety, Trauma and Stressor Related Disorder.pptx
Sagunlohala1
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
The Lifesciences Magazine
 
Pneumothorax and role of Physiotherapy in it.
Pneumothorax and role of Physiotherapy in it.Pneumothorax and role of Physiotherapy in it.
Pneumothorax and role of Physiotherapy in it.
Vishal kr Thakur
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
Dinesh Chauhan
 
Luxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage CenterLuxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage Center
Chandrima Spa Ajman
 
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareLGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
VITASAuthor
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Health Catalyst
 
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyDr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
R3 Stem Cell
 
Gemma Wean- Nutritional solution for Artemia
Gemma Wean- Nutritional solution for ArtemiaGemma Wean- Nutritional solution for Artemia
Gemma Wean- Nutritional solution for Artemia
smuskaan0008
 
Unlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdfUnlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdf
Lift Ability
 
PrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and EngagementPrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and Engagement
PrudentRx Program
 

Recently uploaded (20)

CCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer RehabpptxCCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer Rehabpptx
 
How Effective is Homeopathic Medicine for Anxiety and Stress Relief.pdf
How Effective is Homeopathic Medicine for Anxiety and Stress Relief.pdfHow Effective is Homeopathic Medicine for Anxiety and Stress Relief.pdf
How Effective is Homeopathic Medicine for Anxiety and Stress Relief.pdf
 
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareStem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
 
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic IllnessesPrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic Illnesses
 
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
 
Can Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdfCan Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdf
 
Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.
 
Anxiety, Trauma and Stressor Related Disorder.pptx
Anxiety, Trauma and Stressor Related Disorder.pptxAnxiety, Trauma and Stressor Related Disorder.pptx
Anxiety, Trauma and Stressor Related Disorder.pptx
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
 
Pneumothorax and role of Physiotherapy in it.
Pneumothorax and role of Physiotherapy in it.Pneumothorax and role of Physiotherapy in it.
Pneumothorax and role of Physiotherapy in it.
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
 
Luxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage CenterLuxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage Center
 
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareLGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
 
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyDr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
 
Gemma Wean- Nutritional solution for Artemia
Gemma Wean- Nutritional solution for ArtemiaGemma Wean- Nutritional solution for Artemia
Gemma Wean- Nutritional solution for Artemia
 
Unlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdfUnlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdf
 
PrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and EngagementPrudentRx: A Resource for Patient Education and Engagement
PrudentRx: A Resource for Patient Education and Engagement
 

Victoria McCredie minimizing secondary injury #ISICEM19 #IFAD2019

  • 1. Minimizing secondary injury Victoria McCredie MBChB PhD Assistant Professor University of Toronto
  • 2. Conflicts of interest • Nothing to declare
  • 3. Outline The importance of neuroprotection Secondary brain injury targets Neuroprotection at the bedside
  • 4. Outline The importance of neuroprotection Secondary brain injury targets Neuroprotection at the bedside
  • 6. Maas AI et al. The Lancet Neurology 2008 Macrovascular Microvascular Molecular Importance of differential pathophysiological mechanisms STRUCTURE Microvascular Molecular Inflammation Receptor-mediated damage Oxidative damage Calcium-mediated damage
  • 7. Dynamic and PROGRESSIVE process following injury Adapted from Stocchetti N et al. Crit Care 2013 Excitotoxicity Edema Mitochondrial dysfunction Impaired oxygen diffusion Impaired autoregulation, reduced CBF Energy dysfunction Hours Days Inflammation Cortical depolarizations Neurodegeneration TIME Importance of differential pathophysiological mechanisms
  • 8. Neuroprotective agents • The focus for neuroprotective strategies has mostly been on pharmacological agents • Preliminary results of these agents were often encouraging • Unfortunately, clinical trials using these candidate neuroprotective agents have consistently produced disappointing results • To date, there is no targeted pharmacological treatment that effectively limits the progression of secondary injury SYNAPSE EPO-TBI PEG-SOD Tirilazad Selfotel Traxoprodil Dexanabinol Magnesium Sulfate COBRIT Perhaps deflected attention from the development of neuroprotective strategies and trials addressing everyday ICU management
  • 9. Outcomes improving over time • Despite repeated failures in pharmacological neuroprotection, outcomes for TBI patients have improved • Secular trend in general critical care organization and delivery of care improvements over the past 2 decades • Likely that the organization of intensive treatment has contributed, offering a different kind of neuroprotection based on careful prevention and limitation of intracranial and systemic threats Kramer & Zygun. Can J Anesth 2013 Oct;60(10):966-75 Rosenfeld et al. Lancet. 2012 Sep 22;380(9847)
  • 10. Outline The importance of neuroprotection Secondary brain injury targets Neuroprotection at the bedside
  • 11. Neurophysiologic targets • Hypoxemia/hyperoxemia • Hypotension • Intracranial hypertension • Hypoglycemia • Fever
  • 14. Time is brain Secondary insult ‘dose’
  • 15. Pressure*time burden of intracranial hypertension Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76 ICP ‘dose’Increasing time spent at ICP level ICP value Worse outcome
  • 18. Systolic blood pressure thresholds Systolic blood pressure to decrease mortality: • Patients 15 to 49 yrs: SBP >=110 mmHg • Patients 50 to 69 yrs: at >=100 mmHg • Patients >70 yrs: SBP >=110 mmHg https://www.braintrauma.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed#/:guideline/17-cerebral-perfusion-pressure-thresholds 85 95 105 115 125 135 0 20 40 60 80 100 SBP Age
  • 19. • Recommended target CPP for survival and favorable outcomes between 60-70 mmHg • Unclear whether 60 or 70 mm Hg is the minimum optimal CPP threshold • May depend upon the patient’s autoregulatory status https://www.braintrauma.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed#/:guideline/17-cerebral-perfusion-pressure-thresholds Cerebral perfusion pressure thresholds
  • 20. Assessment of cerebral autoregulation state All comers ICP 20mmHg 30 mins Ability to tolerate burden of intracranial hypertension Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
  • 21. CA intact ICP 20mmHg 150 mins Assessment of cerebral autoregulation state Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
  • 22. CA disrupted ICP 20mmHg 15 mins Assessment of cerebral autoregulation state INABILITY to tolerate burden of intracranial hypertension Güiza F et al Intensive Care Med. 2015 Jun;41(6):1067-76
  • 24. Are these two patients different? ICP 23 ICP 21 PATIENT A PATIENT B Meyfroidt & Citerio. Neurosurgery 2017 Jul 1;81(1):E1
  • 25. Which patient are you more concerned about now? ICP 23 ICP 21 ICP 9 PATIENT A PATIENT B Meyfroidt & Citerio. Neurosurgery 2017 Jul 1;81(1):E1
  • 26. Outline The importance of neuroprotection Secondary brain injury targets Neuroprotection at the bedside
  • 27. Neuroprotection at the bedside Detection of secondary insults at the bedside 1 Translation of neuroprotective strategies at the bedside 2 Integrated neurophysiologic monitoring Standardized management protocol
  • 28. Neuroprotection at the bedside Detection of secondary insults at the bedside 1 Translation of neuroprotective strategies at the bedside 2 Integrated neurophysiologic monitoring Standardized management protocol
  • 29. Why is neurological monitoring so important? 1. First 48 hours, up to 40% of TBI patients show a clinically relevant neurological worsening 2. NO neurological deterioration vs neurological deterioration: • Mortality rate of 9.6% vs 56.4% • Favorable outcome of 67.8% vs 29.1% Brown et al. J Trauma 2007 Jun;62(6):1339-44 Iaccarino et al. J Neurosurg 2014 Apr;120(4):908-18 Juul et al. J Neurosurg 2000 Jan;92(1):1-6 Maas et al. Lancet Neurol 2006 Jan;5(1):38-45 Morris et al. Neurosurgery 1998 Dec;43(6):1369-72 Reasons for neurological deterioration: 1. Increased intracranial volume 63.4% 2. Systemic complications 12.5% 3. No definable cause 12.5% 4. Seizures 6.7% 5. Cerebral ischemia 4.8%
  • 30. Day 2 ICU TBI • 42 year old male • Severe TBI • GCS E1 M4 VT • Brainstem reflexes intact • Sedated for ICP/brain protective ventilation
  • 31. How do we detect secondary brain insults in this comatose patient?
  • 32. Standard monitoring ICP/CPP Impaired brain metabolism Brain tissue hypoxia Reduced cerebral blood flow What we know What we need to know Pressure Flow Oxygenation Metabolism
  • 33. Randomized ICP <20 mmHg ICP <20 mmHg AND PbtO2 >20 mmHg Okonkwo et al. CCM 2017
  • 34. Reduction in brain tissue hypoxia burden ICP only PbtO2 and ICP Tiered PbtO2 management • Decreased total duration of hypoxia by 66% • Decreased average depth of hypoxia by 72% • Reduced area under the curve by 77%Total hypoxia burden (hrs * mmHg)
  • 35. It remains to be demonstrated whether multimodal monitoring-guided therapy is able to improve outcome.
  • 36. Neuroprotection at the bedside Detection of secondary insults at the bedside 1 Translation of neuroprotective strategies at the bedside 2 Integrated neurophysiologic monitoring Standardized management protocol
  • 37. Neurophysiologic-driven protocols in TBI McCredie et al. Crit Care Med. 2018 Jul;46(7):1139-1149
  • 38. How can protocols improve patient care? • Aims to improve outcomes by guiding consistent patient care: 1. Facilitate communication 2. Reduce cognitive load 3. Coordinate the interdisciplinary team 4. Increase the adoption of evidence-based interventions and improve adherence to guidelines Chang et al. Critical Care 2012
  • 39. Neurocritical care interventions ICU STRUCTURE: DEDICATED NCC UNITS VS GENERAL ICU PROCESS OF CARE: PRESENCE OF A STANDARDIZED TBI MANAGEMENT PROTOCOL McCredie et al. Crit Care Med. 2018 Jul;46(7):1139-1149 ICP PbrO2
  • 40. Results Dedicated neurocritical care units were not associated with lower risk-adjusted in-hospital mortality aOR 0.97 (95% CI 0.80-1.19) Standardized management protocols were associated with improved in-hospital mortality aOR 0.77 (95% CI 0.63-0.93) McCredie et al. Crit Care Med. 2018 Jul;46(7):1139-1149
  • 41. In conclusion • Our understanding of secondary brain injury mechanisms and physiologic responses to treatment is continually evolving • Moving forward, we must better understand whether these neurophysiologic parameters are modifiable, and whether modification affects relevant outcomes • Neurophysiologic monitoring at the bedside is a DYNAMIC process, not a single measurement • Integrated neuromonitoring may improve situational awareness and allow an individualized approach to therapy